What does Minerva Neurosciences, Inc. do?
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative…
What is Minerva Neurosciences, Inc.'s P/E and P/B ratio?
Minerva Neurosciences, Inc. has a P/E ratio of -0.1 and a P/B ratio of -0.54.
What is Minerva Neurosciences, Inc.'s debt-to-equity ratio?
Minerva Neurosciences, Inc. has a debt-to-equity ratio of 0.00.
How much does Minerva Neurosciences, Inc. owe compared with what it owns?
Minerva Neurosciences, Inc. owes $3.24 for every $1 it owns (balance sheet Jun 2026), which means it owes more than it owns.
What is Minerva Neurosciences, Inc.'s Positivity rank?
Minerva Neurosciences, Inc. is ranked #6,363 of 6,774 companies globally and #3,638 of 4,000 in United States on PositoAI, with a Positivity Score of -17,502.
Does Minerva Neurosciences, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Minerva Neurosciences, Inc..
Where can I read the latest news about Minerva Neurosciences, Inc.?
Recent headlines about Minerva Neurosciences, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Minerva Neurosciences, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Minerva Neurosciences, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.